In the United States, more than 25 million Americans have asthma; 8.0% of adults (Age 18+ years), and 7.0% of children (Age <18 years) have asthma and was responsible for 3,524 deaths in 2019. (Asthma and Allergy Foundation of America).
Quality's (AHRQ) Evidence-Based Practice Centers: Developed recommendations in better management of Asthma [3]:
- Fractional Exhaled Nitric Oxide Testing: In individual with asthma, Feno may be useful indicator of type 2 (T2) bronchial or eosinophilic inflammation in the airway
- Indoor Allergen Mitigation: Recommends tailored allergen intervention strategies only for individuals with asthma who are exposed to specific allergens and have either symptom based on clinical history or an allergy to substances based on allergy testing.
- Intermittent Inhaled Corticosteroids: Five recommendations for intermittent ICS use can be read through article cited in reference.
- Long-Acting Muscarinic Antagonists: The clinical impact of LAMA treatment in real-world settings is not well understood. Recommendation for use can be reviewed through article cited in reference.
- Immunotherapy in the Treatment of Allergic Asthma: Recommendations call for shared decision making between the clinician and the individual with asthma.
- Bronchial Thermoplasty: The improvements after BT were small, and the harms of BT were moderate.
